PSMA-targeted Therapy Development

PSMA is a cell membrane protein that is highly expressed on the surface of prostate cancer cells, making it an ideal imaging and therapeutic target. At Alfa Cytology, we have cutting-edge technology and a specialized platform designed to provide a comprehensive one-stop service for the development of PSMA-targeted therapies for prostate cancer.

Introduction to PSMA-targeted Therapy

Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is a zinc ion-dependent metalloprotease. It is a transmembrane glycoprotein located on the cell membrane and is specifically highly expressed in prostate cancer. Furthermore, its expression level correlates with tumor aggressiveness and has become an ideal imaging and therapeutic target for prostate cancer therapy.

Fig. 1 Tumor therapies targeting PSMA. (Wang, F., et al. 2022)

Various PSMA-targeted therapies have been developed for the treatment of prostate cancer, including radioligand therapy, antibody therapy, cellular immunotherapy, photodynamic therapy, imaging-guided surgery, and ultrasound-mediated nanobubble destruction.

PSMA-targeted Therapy Development for Prostate Cancer

Our Services

As a molecular target for prostate cancer, PSMA has been extensively studied in the past decades. Currently, a large body of evidence suggests that PSMA-targeted therapy is critical for the therapy of prostate cancer. At Alfa Cytology, we have a professional team to provide you with 24-hour end-to-end development services to ensure that the entire PSMA-targeted therapy development process is fast-tracked.

Workflow for PSMA-targeted Therapy Development

Drug Discovery

The process of drug discovery typically involves several stages, including target identification and validation, hit identification and lead optimization, and preclinical testing.

Efficacy Evaluation

In vitro efficacy evaluation offers rapid, high-throughput initial screening, while in vivo efficacy evaluation provides necessary data to validate drug efficacy and safety in a physiological setting.

DMPK/ADME

Assessing the in vitro ADME and in vivo PK of cancer drugs ensures their efficacy and safety in living organisms, offering vital data for optimizing dosage and dosing schedules.

Safety Assessment

Local toxicity and safety of cancer drugs are assessed using general toxicology, genetic toxicology, reproductive toxicology, and immunotoxicity of cancer drugs.

One-stop Solutions for PSMA-targeted Therapy Development

In the arena of prostate cancer therapy, PSMA-targeted therapy have become an increasingly important area of research. Alfa Cytology aims to provide customized one-stop PSMA-targeted therapy development services in the field of prostate cancer therapy. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.